Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 9/20 | 0.73 |
| ▸ | S1PR3 | Q99500 | 8/20 | 0.73 |
| ▸ | S1PR4 | O95977 | 6/20 | 0.73 |
| ▸ | S1PR5 | Q9H228 | 5/20 | 0.73 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | PLA2G4B | P0C869 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | RARB | P10826 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3289846 | 1.00 | S1PR1 (0.73) | S1PR1S1PR3S1PR4S1PR5TP53 | |
| SCHEMBL13932767 | 0.85 | S1PR1 (0.67) | S1PR1S1PR3S1PR4S1PR5TP53 | |
| SCHEMBL3291632 | 0.85 | S1PR1 (1.00) | S1PR1S1PR3S1PR4S1PR5TP53 | |
| SCHEMBL2632242 | 0.85 | S1PR1 (0.67) | S1PR1S1PR3S1PR4S1PR5TP53 | |
| SCHEMBL3291628 | 0.85 | S1PR1 (1.00) | S1PR1S1PR3S1PR4S1PR5TP53 | |
| SCHEMBL3291932 | 0.84 | S1PR1 (1.00) | S1PR1S1PR3S1PR4S1PR5TP53 | |
| SCHEMBL3291940 | 0.84 | S1PR1 (1.00) | S1PR1S1PR3S1PR4S1PR5TP53 | |
| SCHEMBL13628909 | 0.82 | S1PR1 (0.59) | S1PR1S1PR3S1PR4S1PR5LMNA | |
| SCHEMBL296505 | 0.81 | S1PR1 (0.73) | S1PR1S1PR3S1PR4S1PR5LMNA | |
| SCHEMBL3509655 | 0.81 | S1PR1 (0.73) | S1PR1S1PR3S1PR4S1PR5LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7728020-B2 | Amino acid derivatives | NOVARTIS AG (CH) | 2010-06-01 | — | — | US | claimed |
| US-20070135501-A1 | Amino acid derivatives | NOVARTIS AG (CH) | 2007-06-14 | — | — | US | claimed |
| EP-1725519-A1 | AMINO ACID DERIVATIVES | Novartis AG (CH) | 2006-11-29 | — | — | EP | claimed |
| WO-2005085179-A1 | AMINO ACID DERIVATIVES | NOVARTIS AG (CH) | 2005-09-15 | — | — | WO | claimed |
| US-7728020-B2 | Amino acid derivatives | NOVARTIS AG (CH) | 2010-06-01 | — | — | US | disclosed |
| US-7728020-B2 | Amino acid derivatives | NOVARTIS AG (CH) | 2010-06-01 | — | — | US | disclosed |
| US-7728020-B2 | Amino acid derivatives | NOVARTIS AG (CH) | 2010-06-01 | — | — | US | disclosed |
| US-20070135501-A1 | Amino acid derivatives | NOVARTIS AG (CH) | 2007-06-14 | — | — | US | disclosed |
| US-20070135501-A1 | Amino acid derivatives | NOVARTIS AG (CH) | 2007-06-14 | — | — | US | disclosed |
| US-20070135501-A1 | Amino acid derivatives | NOVARTIS AG (CH) | 2007-06-14 | — | — | US | disclosed |
| EP-1725519-A1 | AMINO ACID DERIVATIVES | Novartis AG (CH) | 2006-11-29 | — | — | EP | disclosed |
| WO-2005085179-A1 | AMINO ACID DERIVATIVES | NOVARTIS AG (CH) | 2005-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135501-A1 | Amino acid derivatives | AADAT, BCAT2, BCAT1 | S1PR1 4747/4885S1PR3 4514/4885S1PR4 4726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.